ライフサイエンスコーパス: RET

1 RET can only generate ROS when mitochondria are well pol

2 RET deficiency, for example, leads to intestinal agangli

3 RET encodes a transmembrane receptor that is 20 exons lo

4 RET fusions were identified in 23 cases, 15 females [2.2

5 RET gene rearrangements retaining the kinase domain are

6 RET is a receptor tyrosine kinase (RTK) that plays essen

7 RET is a transmembrane growth factor receptor.

8 RET is dynamically expressed during myogenic progression

9 RET is thus an attractive therapeutic target in patients

10 RET mutations occur in 70% of medullary thyroid cancers,

11 RET mutations were associated with differentiation and m

12 RET rearrangements are found in 1-2% of non-small-cell l

13 RET rearrangements as well as BRAF and RAS mutations dri

14 RET receptor tyrosine kinase is a driver oncogene in hum

15 RET was performed on 24 immature premolars with an autol

16 RET(DeltaE345), in contrast, displays higher baseline au

17 0.9-4.0] vs 7.0 [IQR, 3.5-13.0]; P < .001), RET (4.6 [IQR, 1.7-8.7] vs 7.0 [IQR, 2.6-13.0]; P = .004

18 , VHL) tumors than for hereditary cluster 2 (RET, NF1) and sporadic tumors (P < 0.01 and P < 0.05, re

19 ib complex to 1.87 angstrom resolution and a RET(G810A) kinase domain crystal structure to 1.99 angst

20 tic or unresectable lung cancer harbouring a RET rearrangement, Karnofsky performance status higher t

21 By RNA-seq analysis, we identify a RET rearrangement in the tumour material of a patient wh

22 Nintedanib is a RET TKI that inhibits the vandetanib-resistant RET(G810A

23 ) and from 2 patients with S-HSCR (without a RET mutation), as well as RET(+/-) and RET(-/-) iPSCs.

24 aling complex, agents that bind and activate RET directly and independently of GFRalpha1 expression a

25 These ligands activate RET tyrosine kinase and afford trophic signals irrespect

26 Aberrantly activated RET is found in several types of human cancer and is a t

27 ons of Q121 generated analogs that activated RET irrespective of GFRa1 expression.

28 Activating RET mutations are associated with different phenotypes o

29 broad activity across tumors with activating RET alterations.

30 red in the clinic for tumors with activating RET gene alterations with modest clinical efficacy.

31 After RET, 1-RM increased in Y (+35 +/- 4%) and O (+25 +/- 3%;

32 kbp5 mRNA expression following EXT and after RET.

33 ained ROS production by this mechanism after RET-driven ROS production has ceased.

34 multikinase inhibitor with activity against RET that produced a 10% overall response in unselected p

35 mors are generally driven by fusions of ALK, RET, NTRK1/3, MET, ROS1 and BRAF(1,2).

36 ultikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune micro

37 cur in 70% of medullary thyroid cancers, and RET fusions occur rarely in other thyroid cancers.

38 DSG2-deficient and RET-deficient Caco2 cells revealed that GDNF specificall

39 that, like full-length RET, RET(DeltaE3) and RET(DeltaE345) are trafficked to the cell surface, inter

40 5 and are referred to as RET(Delta) (E3) and RET(Delta) (E345), respectively.

41 turn, these TFs are controlled by EDNRB and RET in a dose-dependent manner.

42 d dose-dependent enhancement of both EXT and RET.

43 ction between the atypical cadherin FAT4 and RET, a tyrosine kinase receptor essential for kidney dev

44 induced spontaneous lung tumor formation and RET activation.

45 mparisons of RET-nintedanib, RET(G810A), and RET-vandetanib crystal structures suggested that the sol

46 GDNF activity to systems in which GFRa1 and RET are both present, a scenario that may constrain GDNF

47 tive functional cross-talk between GFRa1 and RET.

48 s displayed intense tyrosine hydroxylase and RET proto-oncogene expression in nigral neurons in the p

49 Novel configurations of BRAF, NTRK3, and RET gene fusions resulting from chromosomal translocatio

50 lean mass and leg strength gains when PS and RET were used than with RET alone, with the standard mea

51 ular endothelial growth factor receptors and RET (rearranged during transfection) have been used when

52 out a RET mutation), as well as RET(+/-) and RET(-/-) iPSCs.

53 panel) to those obtained from ALK, ROS1 and RET FISH on 51 clinical specimens.

54 ALK, ROS1 and RET gene fusions are important predictive biomarkers for

55 AG1(TM-) cells were unresponsive to TRKA and RET signaling, two RTKs that induce neuronal differentia

56 neurotrophin receptors TrkA, TrkB, TrkC, and RET and the sensory neurofilament peripherin.

57 BRAF(V600E)- and RET/PTC3-expressing PcCL3 cells were used as cellular mo

58 immunostaining of CCH and MTC using an anti-RET antibody demonstrated increased RET expression.

59 ily of small molecules (Q compounds) acts as RET agonists.

60 or exons 3, 4, and 5 and are referred to as RET(Delta) (E3) and RET(Delta) (E345), respectively.

61 S-HSCR (without a RET mutation), as well as RET(+/-) and RET(-/-) iPSCs.

62 Appropriately balanced RET signaling is of crucial importance during embryonic

63 Because RET can only generate ROS when mitochondria are fully po

64 this explanation may be incomplete, because RET on reperfusion is self-limiting and therefore transi

65 tion, whereas a physical interaction between RET/PTC3 and STAT1, followed by a direct tyrosine phosph

66 ponents of the dynamic relationships between RET and its GFRa co-receptor and provides RET agonist sc

67 In comparison to Y, O displayed blunted RET-induced increases in muscle thickness (at 3 and 6 we

68 entration 50 (IC(50)) of <0.003 muM for both RET and VEGFR2.

69 ands the ENS development GRN to include both RET and EDNRB, uncovers the mechanistic basis for RET-ED

70 The balanced synchronous inhibition of both RET and VEGFR2, as well the resistance to demethylation,

71 ely prevented formation of tumors induced by RET/C634Y-transformed cells, while it weakened, but did

72 R2 and proliferation of cells transformed by RET.

73 KIF5B-RET in females [80% (12/15)] and CCDC6-RET in males [50% (4/8)], along with some rare RET fusio

74 the number of cigarettes per day (EPHX2-CLU, RET and CUX2-ALDH2), three loci associated with smoking

75 nflammatory changes compared to conventional RET.

76 Conversely, RET/PTC3-expressing cells were characterized by a high I

77 the interaction of GFRAL with the coreceptor RET.

78 nts with RET-rearranged lung cancers defines RET rearrangements as actionable drivers in patients wit

79 In detail, RET/PTC3 induced STAT1 overexpression and phosphorylatio

80 /CCH predisposition do not have a detectable RET mutation.

81 conditions (70 genes), retinal dystrophies (RET; 235 genes), and albinism (15 genes), as well as add

82 Finally, specific ablation of early RET+ dDH neurons increases basal and chronic pain, where

83 nd pain pathways and suggest that some early RET+ dDH neurons could function as pain "gating" neurons

84 These early RET+ dDH neurons receive excitatory as well as polysynap

85 iluminescence resonance energy transfer (ECL-RET) approach, Fe3O4@SiO2/dendrimers/QDs exhibited ampli

86 ing ability to dose for clinically effective RET inhibition.

87 fic, low-frequency missense variant encoding RET p.Asp489Asn (rs9282834, conditional OR = 20.3, condi

88 We used these analogs to examine RET-GFRa1 interactions and show that GFRa1 can influence

89 aled abnormal ureteric budding and excessive RET signaling.

90 d CCSD(T) calculations and the experimental (RET-PES) data.

91 ctor, and are selective for cells expressing RET.

92 olymer pluronic F-127-folic acid (F-127-FA), RET-BDP molecules can form uniform and small organic nan

93 nd EDNRB, uncovers the mechanistic basis for RET-EDNRB epistasis and emphasizes how functionally diff

94 NPA101.3 a potential clinical candidate for RET-driven cancers.

95 ons, including SLC39A8-RET, ITIH2-RET, FYCO1-RET and SLC25A36-RET in females, and MIR3924-RET, ZBTB41

96 syndrome caused mainly by Met918Thr germline RET mutation, and characterised by medullary thyroid car

97 perplasia (CCH), is associated with germline RET mutations causing multiple endocrine neoplasia type

98 Mechanistically, activation of the GFRAL-RET pathway induces expression of genes involved in lipi

99 ular region ternary complexes of GDF15/GFRAL/RET, GDNF/GFRalpha1/RET, NRTN/GFRalpha2/RET and ARTN/GFR

100 To dissect the GDNF-GFRalpha1-RET signaling complex, agents that bind and activate RET

101 complexes of GDF15/GFRAL/RET, GDNF/GFRalpha1/RET, NRTN/GFRalpha2/RET and ARTN/GFRalpha3/RET.

102 FRAL/RET, GDNF/GFRalpha1/RET, NRTN/GFRalpha2/RET and ARTN/GFRalpha3/RET.

103 The NRTN/GFRalpha2/RET dimeric complex further pack into a tetrameric assem

104 1/RET, NRTN/GFRalpha2/RET and ARTN/GFRalpha3/RET.

105 f female patients with lung cancer harboring RET fusion gene for the first time.

106 n female patients with lung cancer harboring RET fusion gene.

107 ar profile, includingKRAS,EGFR,ALK,BRAF,HER2,RET,MET, andROS, did not reveal an actionable abnormalit

108 sulted in little angular deflection but high RET to both partners, a very unusual combination.

109 However, RET activation by these ligands is constrained by GFRalp

110 ene, complementing four known drivers (HRAS, RET, EPAS1, and NF1).

111 he proposal that loss of Fat4 hyperactivates RET signaling.

112 redisposition to MTC/CCH and no identifiable RET mutation.

113 lar states of ENS progenitors and identified RET as a regulator of neurogenic commitment.

114 -crystal structure disclosed that Leu-730 in RET engages in hydrophobic interactions with the piperaz

115 hway was instrumental for IDO1 expression in RET/PTC3 expressing cells.

116 The application of GM in RET led to favorable clinical outcomes of root developme

117 for a physiologic role of these isoforms in RET pathway function.

118 aganglionosis (with the G731del mutation in RET) and from 2 patients with S-HSCR (without a RET muta

119 led to speculation of a 'Janus mutation' in RET that causes overactivation or impairment of RET acti

120 Eight of the DNMs we identified occur in RET, the main HSCR gene, and the remaining 20 DNMs resid

121 ing mutations in CSF1R and rearrangements in RET and ALK that conferred dramatic responses to selecti

122 the state-of-the-art treatment strategies in RET-dependent cancers.

123 eration, activation of the ERE and increased RET expression.

124 hts into a novel mechanism causing increased RET expression in tumourigenesis.

125 an anti-RET antibody demonstrated increased RET expression.

126 mechanism that can be overcome by increasing RET ligand concentration.

127 teractions and show that GFRa1 can influence RET-mediated signaling and enhance or diminish AKT Ser/T

128 ibody, 3P10, that targets GFRAL and inhibits RET signaling by preventing the GDF15-driven interaction

129 males, and MIR3924-RET, ZBTB41-RET and ITGA8-RET in males.

130 re RET fusions, including SLC39A8-RET, ITIH2-RET, FYCO1-RET and SLC25A36-RET in females, and MIR3924-

131 MRM retrieval + ketamine (RET + KET) effectively reduced the reinforcing effects o

132 HSCs treated with the key RET ligand/coreceptor complex, glial-derived neurotrophi

133 KIF5B-RET was the predominant fusion type identified in 16 (62

134 s well as 1 EML4-ALK gene fusion and 1 KIF5B-RET gene fusion.

135 es, including EML4-ALK, CD74-ROS1, and KIF5B-RET.

136 atic lung adenocarcinoma, who harbored KIF5B-RET fusion and had highly positive PD-L1 staining, recei

137 The most common fusions were KIF5B-RET in females [80% (12/15)] and CCDC6-RET in males [50%

138 Activating receptor tyrosine kinase RET (rarranged during transfection) gene alterations hav

139 the gene encoding receptor tyrosine kinase (RET).

140 oforms, demonstrating that, like full-length RET, RET(DeltaE3) and RET(DeltaE345) are trafficked to t

141 horylated in a similar manner to full-length RET.

142 e ability to heterodimerize with full-length RET.

143 system to test the effects of GDNF-mediated RET activation, we demonstrate the concurrent developmen

144 nal study in patients carrying the Met918Thr RET variant with no age restrictions.

145 RET and SLC25A36-RET in females, and MIR3924-RET, ZBTB41-RET and ITGA8-RET in males.

146 igmentosa, monotherapy with a small-molecule RET agonist activates survival signals and reduces neuro

147 do-distyryl-BODIPY) to form a dyad molecule (RET-BDP).

148 and without PRC2 loss (MPNST(LOSS) vs. MPNST(RET)).

149 A3, FOXA1, EGFR, CDH1, DSP, KRT7, FBP1, MYB, RET, KRT8, MUC1, and ERBB2-genes which are responsible f

150 NCOA4-RET and LMNA-NTRK1 fusions and NRG1 and GNAS amplificati

151 ALK(F1174L) induces NEFM, RET, and VACHT and results in decreased expression of pr

152 in neurons that also stained for neurturin, RET, and tyrosine hydroxylase.

153 Comparisons of RET-nintedanib, RET(G810A), and RET-vandetanib crystal structures sugges

154 on did not affect sensitivity to nintedanib, RET(L881V) was resistant to nintedanib analogs lacking a

155 ce, PLP1 cells that co-express S100b but not RET also give rise to neurons following colitis.

156 GFR2, FGFR3, MET, NRG1, NTRK1, NTRK2, NTRK3, RET and ROS1 on eleven formalin fixed and paraffin embed

157 or without RNA sequencing for ALK/ROS1/NTRKs/RET fusions, next-generation sequencing for HER2/PIK3CAe

158 ism and diversification in the activation of RET by different ligands.

159 1 expression and the oncogenic activation of RET in thyroid carcinoma and describe the involved signa

160 GFRalpha1) and signals through activation of RET tyrosine kinase.

161 no report on the genetic characteristics of RET fusions in female patients with lung cancer is avail

162 Comparisons of RET-nintedanib, RET(G810A), and RET-vandetanib crystal s

163 We also demonstrate that the effects of RET and NRG1 are universal across European and Asian anc

164 Trk fused Gene (TFG) fused to the 3' end of RET tyrosine kinase leading to a TFG-RET fusion which tr

165 -based assays to regulate the endocytosis of RET.

166 that causes overactivation or impairment of RET activity depending on the cellular context.

167 ramatic responses to selective inhibition of RET (selpercatinib) and crizotinib, respectively, in pat

168 by perineurial macrophages, or inhibition of RET with shRNA or a small-molecule inhibitor, reduced pe

169 y preventing the GDF15-driven interaction of RET with GFRAL on the cell surface.

170 profile are poised to alter the landscape of RET-dependent cancers.

171 A genuine ligand of RET receptor ectodomain was identified, which acts as an

172 cant association between the localization of RET mutations and the expression of three genes: NNAT (s

173 ions, induce a specific dimerization mode of RET that is poised to bring the two kinase domains into

174 Drug-sensitivity profiling of RET(L881V) revealed that it remains sensitive to ninteda

175 ovide structural insights into resistance of RET mutants against the TKIs nintedanib and vandetanib.

176 determined the X-ray co-crystal structure of RET kinase domain-nintedanib complex to 1.87 angstrom re

177 ces have been made in selective targeting of RET and BRAF in patients with medullary and anaplastic t

178 on profile of MTC with regard to the type of RET gene mutation and the cancer genetic background (her

179 view summarizes the current understanding of RET alterations and the state-of-the-art treatment strat

180 eptor alpha like (GFRAL)-Ret proto-oncogene (RET) signaling complex in brainstem neurons that mediate

181 herapeutic target in patients with oncogenic RET alterations.

182 arcinomas harboring BRAF (V600E) mutation or RET gene rearrangements (i.e., BRAF-like tumors) and ind

183 s harboring BRAF (V600E) somatic mutation or RET oncogene rearrangement and dramatically reduced moti

184 s (Hirschsprung disease), whereas overactive RET can lead to multiple endocrine neoplasia (MEN) syndr

185 and exercise strategies, especially PS plus RET, to effectively improve the physical activity and he

186 en RET and its GFRa co-receptor and provides RET agonist scaffolds for drug development.

187 T in males [50% (4/8)], along with some rare RET fusions, including SLC39A8-RET, ITIH2-RET, FYCO1-RET

188 We show a role for the GFL receptor, RET, at the cell surface of HSCs in mediating sustained

189 and cell lines, we demonstrate that reduced RET expression propagates throughout its gene regulatory

190 nd inhibition of HUWE1 significantly reduces RET-mediated oncogenesis.

191 tion of CRE variants synergistically reduces RET expression and its effects throughout the GRN.

192 mbly of the RET-GFRA1-GDNF complex, reducing RET signaling.

193 a non-autonomous role for Fat4 in regulating RET signaling.

194 Multiple clinically relevant RET protein-tyrosine kinase inhibitors (TKIs) have been

195 T TKI that inhibits the vandetanib-resistant RET(G810A) mutant.

196 We also identified a vandetanib-resistant RET(L881V) mutation previously found in familial medulla

197 The resulting RET-BDP shows significantly enhanced absorption and sing

198 s, demonstrating that, like full-length RET, RET(DeltaE3) and RET(DeltaE345) are trafficked to the ce

199 XT training and then examined EXT retention (RET) 24 h later to determine whether dexamethasone suppr

200 Retapamulin-enhanced Ribo-seq analysis (Ribo-RET) not only allowed mapping of conventional initiation

201 N 2A syndrome demonstrated the moderate risk RET p.Val804Met (protein valine at residue 804 replaced

202 druggable kinase fusions involving ALK, ROS, RET, NTRK and FGFR gene families were detected in bladde

203 Oncogenic kinase fusions of ALK, ROS1, RET, and NTRK1 act as drivers in human lung and other ca

204 u hybridization and negative for EGFR, ROS1, RET, BRAF, KRAS, and other oncogenes.

205 Different from most of RTKs, RET requires not only its cognate ligands but also co-re

206 ce to these next-generation highly selective RET inhibitors is an area of active research.

207 ancers, the efficacy and safety of selective RET inhibition are unknown.

208 inical validation of highly potent selective RET inhibitors (pralsetinib, selpercatinib) demonstratin

209 Significantly, RET and EDNRB expression is regulated by their shared us

210 C39A8-RET, ITIH2-RET, FYCO1-RET and SLC25A36-RET in females, and MIR3924-RET, ZBTB41-RET and ITGA8-RE

211 ith some rare RET fusions, including SLC39A8-RET, ITIH2-RET, FYCO1-RET and SLC25A36-RET in females, a

212 r or syndromic, 37.5% (3 of 8 cases solved); RET, 42.8% (21 of 49 cases solved); and congenital catar

213 Some RET mutations are associated with both intestinal agangl

214 from these neuron-derived iPSCs called STEM-RET.

215 r to Ret(-/-) cells, and that YAP suppresses RET signalling and tip identity.

216 Suppressing RET activity using Sunitinib, a clinically-approved tyro

217 a, a lead compound, Q525, afforded sustained RET activation and prevented photoreceptor neuron loss i

218 clinical drug candidate Pz-1, which targets RET and VEGFR2.

219 01.3 inhibited phosphorylation of all tested RET oncoproteins as well as VEGFR2 and proliferation of

220 TFG-RET oligomerises in a PB1 domain-dependent manner and ol

221 end of RET tyrosine kinase leading to a TFG-RET fusion which transforms immortalized human thyroid c

222 -dependent manner and oligomerisation of TFG-RET is required for oncogenic transformation.

223 Expression of TFG-RET leads to the upregulation of HUWE1 and inhibition of

224 ent and Ret mutant mice, we demonstrate that RET-mediated GDNF signaling in UGS increases proliferati

225 We previously demonstrated that RET transcription in the ENS is controlled by an extensi

226 Signaling experiments indicate that RET(DeltaE3) is phosphorylated in a similar manner to fu

227 It is well known that RET mutations affecting the cysteine-rich region of the

228 e and MEN-associated tumors, but rather that RET overstimulation alone is enough to cause both phenot

229 ysis of human cancer specimens revealed that RET expression is upregulated during PDAC tumorigenesis.

230 Finally, we show that RET drives a multifaceted intracellular signaling pathwa

231 Taken together, our findings show that RET is upregulated during pancreas tumorigenesis and its

232 nding of atom-molecule scattering shows that RET usually occurs by only a simple "bump" between partn

233 The RET proto-oncogene, a tyrosine kinase receptor, is widel

234 The RET-nintedanib co-crystal structure disclosed that Leu-7

235 a1), and the resulting complex activates the RET receptor tyrosine kinase and subsequent downstream s

236 alpha-mediated activation of the ERE and the RET promoter contains three EREs.

237 SC using CRISPR/Cas9 editing, as well as the RET G731del mutation that causes Hirschsprung disease wi

238 tic screening for a germline mutation at the RET gene was performed in 11 family members.

239 ommon disease-susceptibility variants at the RET, SEMA3 and NRG1 loci have been detected through geno

240 d that BM-derived macrophages expressing the RET ligand GDNF are highly abundant around nerves invade

241 disorder caused by germline mutations in the RET (formerly MEN2A, MEN2B) proto-oncogene located on ch

242 entified an intronic enhancer variant in the RET gene disrupting SOX10 binding and increasing Hirschs

243 cing to phase two variants 9 kb apart in the RET gene.

244 CRISPR/Cas9 correction of the RET G731del and VCL M209L mutations in iPSCs restored th

245 zygous mutations in the coding region of the RET gene cause a severe form of Hirschsprung disease (to

246 We also noticed that the site of the RET gene mutation slightly influenced the gene expressio

247 Removal of one copy of the RET ligand Gdnf rescues Fat4(-/-) kidney development, su

248 n particular, epigenetic derepression of the RET proto-oncogene by loss of PRC2 recruitment, and acti

249 ) can be caused by germline mutations of the RET proto-oncogene or occurs as a sporadic form.

250 ression of FAT4 perturbs the assembly of the RET-GFRA1-GDNF complex, reducing RET signaling.

251 s of PRC2 recruitment, and activation of the RET/p38 signaling axis, play a crucial role in mediating

252 ules that are genuine ligands binding to the RET extracellular domain.

253 DSG2-mediated intercellular adhesion via the RET receptor.

254 When in trans with the RET intron 1 enhancer risk allele, rs9282834 increases t

255 ncerns for regenerative endodontics therapy (RET).

256 ) have been identified, but how TKIs bind to RET is unknown except for vandetanib.

257 lockade, our results extended this effect to RET and NTRK1 blockade and uncovered the other additiona

258 0.1% day(-1) ), MPS increased in response to RET only in Y (3 weeks, Y: 1.61 +/- 0.1% day(-1) ; O: 1.

259 Hypertrophic responses to RET with age are diminished compared to younger individu

260 Resistance exercise training (RET) has a beneficial effect on muscle protein synthesis

261 Resistance exercise training (RET) is one of the most effective strategies for prevent

262 c responses to resistance exercise training (RET).

263 1 (ROS1) and rearranged during transfection (RET)) has established an oncogene-centric molecular clas

264 Rearranged during transfection (RET), a receptor tyrosine kinase that is activated by th

265 Knowledge of rotational energy transfer (RET) involving carbon monoxide (CO) molecules is crucial

266 nted to utilize a resonance energy transfer (RET) mechanism to construct a novel dyad photosensitizer

267 lex binds to and activates the transmembrane RET tyrosine kinase to signal through intracellular Akt/

268 succinate-driven reverse electron transport (RET) through complex I as a major source of damaging rea

269 Succinate-driven reverse electron transport (RET) through complex I is hypothesized to be a major sou

270 nt, as well as those with previously treated RET fusion-positive thyroid cancer, in a phase 1-2 trial

271 In 19 patients with previously treated RET fusion-positive thyroid cancer, the percentage who h

272 of human cancer and is a target for treating RET aberration-associated cancer.

273 Thus, FAT4 interacts with RET to fine-tune RET signaling, establishing a juxtacrine mechanism contr

274 in response to PS in older people undergoing RET remains unclear.This study was conducted to identify

275 lity improvements in older people undergoing RET.We included 17 RCTs; the overall mean +/- SD age and

276 physical function of older people undergoing RET.We performed a comprehensive search of online databa

277 9 +/- 3 years), performed 6 weeks unilateral RET (6 x 8 repetitions, 75% of one repetition maximum (1

278 This work validates RET receptor as a druggable therapeutic target and provi

279 rosine kinase inhibitor, targets MET, VEGFR, RET, ROS1, and AXL, which are implicated in lung cancer

280 a novel tyrosine kinase inhibitor of VEGFR2, RET, and EGFR, all of which are in involved in the patho

281 x subunits B and D, von Hippel-Lindau (VHL), RET, and neurofibromin 1 (NF1).

282 In response to 6 weeks RET, we found blunted hypertrophic responses with age ar

283 pread genetic susceptibility associated with RET.

284 PS.Compared with RET alone, PS combined with RET may have a stronger effect in preventing aging-relat

285 levant gains in response to PS.Compared with RET alone, PS combined with RET may have a stronger effe

286 Multikinase inhibitors with RET inhibitor activity, such as cabozantinib and vandeta

287 istically, we found that FAT4 interacts with RET through extracellular cadherin repeats.

288 Thus, FAT4 interacts with RET to fine-tune RET signaling, establishing a juxtacrin

289 st 24 genes and seven chromosomal loci, with RET and EDNRB as its major genes.

290 ches will be needed to improve outcomes with RET-directed targeted treatment.

291 In patients with RET-altered thyroid cancers, the efficacy and safety of

292 In 88 patients with RET-mutant medullary thyroid cancer who had not previous

293 irst 55 consecutively enrolled patients with RET-mutant medullary thyroid cancer who had previously r

294 We enrolled patients with RET-mutant medullary thyroid cancer with or without prev

295 , 2012, and April 30, 2016, 26 patients with RET-rearranged lung adenocarcinomas were enrolled and gi

296 The accrual of patients with RET-rearranged lung cancer to this protocol has been com

297 ed activity of cabozantinib in patients with RET-rearranged lung cancers defines RET rearrangements a

298 he activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase

299 th gains when PS and RET were used than with RET alone, with the standard mean differences (SMDs) bei

300 5A36-RET in females, and MIR3924-RET, ZBTB41-RET and ITGA8-RET in males.